financetom
Business
financetom
/
Business
/
Rumble Insider Sold Shares Worth $2,154,000, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rumble Insider Sold Shares Worth $2,154,000, According to a Recent SEC Filing
Apr 3, 2024 6:40 AM

09:29 AM EDT, 04/03/2024 (MT Newswires) -- Claudio Ramolo, Chief Content Officer, on April 01, 2024, sold 300,000 shares in Rumble (RUM) for $2,154,000. Following the Form 4 filing with the SEC, Ramolo has control over a total of 6,203 shares of the company, with 6,203 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1830081/000121390024029596/xslF345X03/ownership.xml

Price: 7.31, Change: -0.01, Percent Change: -0.14

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Gainers
Top Premarket Gainers
Feb 24, 2025
07:37 AM EST, 02/24/2025 (MT Newswires) -- AtlasClear Holdings ( ATCH ) shares more than doubled pre-bell Monday following a 1.7% loss in the previous session. Oriental Rise ( ORIS ) stock was 64% higher after Friday's 1.8% gain. ISpecimen ( ISPC ) shares were up 36% after a 3.9% fall on Friday. VirnetX Holding ( VHC ) stock was...
Kaspi.kz's Q4 Net Income, Revenue Increase
Kaspi.kz's Q4 Net Income, Revenue Increase
Feb 24, 2025
07:34 AM EST, 02/24/2025 (MT Newswires) -- Kaspi.kz (KSPI) reported Q4 net income Monday of 316.40 billion Kazakhstani tenge ($628.6 million), up from 247.99 billion Kazakhstani tenge a year earlier. Four analysts polled by FactSet expected 323.25 billion Kazakhstani tenge. Revenue for the quarter ended Dec. 31 was 730.35 billion Kazakhstani tenge, up from 570.79 billion Kazakhstani tenge a year...
Glaukos's Corneal Disease Drug Accepted for FDA Review
Glaukos's Corneal Disease Drug Accepted for FDA Review
Feb 24, 2025
07:32 AM EST, 02/24/2025 (MT Newswires) -- Glaukos Corp ( GKOS ) said Monday that the US Food and Drug Administration has accepted its corneal disease drug Epioxa for review, with a goal date of Oct. 10. Epioxa is a corneal cross-linking iLink therapy for the treatment of keratoconus, a sight-threatening corneal disease. The application includes data from two phase...
Wallbox Raises $10 Million in Private Placement of Shares
Wallbox Raises $10 Million in Private Placement of Shares
Feb 24, 2025
07:34 AM EST, 02/24/2025 (MT Newswires) -- Wallbox ( WBX ) said Monday it raised about $10 million through a private placement 26,707,142 class A ordinary shares. Investors included Inversiones Financieras Perseo, Orilla Asset Management, and Wallbox ( WBX ) Chief Executive Enric Asuncion. The company said the investment provides the necessary capital to support the global sales of its...
Copyright 2023-2026 - www.financetom.com All Rights Reserved